Temozolomide-induced desquamative skin rash in a patient with metastatic melanoma

Pharmacotherapy

Volumn 28, Issue 3, 2008, Pages 406-409

  Pick, Amy M ^a,b   Neff, William J ^a   Nystrom, Kelly K ^b  

^a Methodist Hospital Omaha   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Desquamative; Metastatic melanoma; Rash; Temozolomide

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; CILASTATIN PLUS IMIPENEM; CORTICOSTEROID; HYDROCORTISONE; LEVOFLOXACIN; LINEZOLID; NAFCILLIN; TEMOZOLOMIDE; TOPICAL AGENT; TRIAMCINOLONE; VANCOMYCIN;

ADULT; ANAMNESIS; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CREAM; DERMATITIS; DESQUAMATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ERYTHEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; MELANOMA; METASTASIS; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRURITUS; PUNCH BIOPSY; RASH; STAPHYLOCOCCUS AUREUS; VITAL SIGN;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG ERUPTIONS; FEMALE; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 40149105110     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.3.406     Document Type: Article

References (12)

1. Schering Corp. Temodar (temozolomide) package insert. Kenilworth, NJ; 2006.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
3. National Comprehensive Cancer Network. Melanoma. Rockland, PA. Version 2. 2007. Available from www.nccn.org. Accessed January 15, 2008.
4. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
5. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998;58:4363-7.
6. Boogerd W, deGast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation? Cancer 2007;109(2):306-12.
7. Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22(11):2101-7.
8. Bafaloukos D, Tsoutsos D, Fountzilas G, et al. The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Melanoma Res 2004;14(4):289-94.
9. Hall DJ, Burns JC, Goplerud DR. Kaposi's sarcoma of the vulva: a case report and brief review. Obstet Gynecol 1979; 54(4):478-83.
10. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4(8): 561-72.
11. Bolognia JL, Braverman IM. Skin manifestations in internal disease. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 2005:296-311.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.